Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051038 · ClinicalTrials.gov registry record · Phase 2
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
A Phase 2 study of Hepatitis B, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00051038: Completed Phase 2 study of Hepatitis B, sponsored by Bristol-Myers Squibb.
NCT00051038 is a Phase 2 study of Hepatitis B that has completed, run by Bristol-Myers Squibb. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051038, a Phase 2 study of Hepatitis B, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
Conditions Studied
Interventions
- DRUG Entecavir
Study Locations (5)
Connecticut
- Local Institution - New Haven
Florida
- Local Institution - Altamonte Springs
Kentucky
- Local Institution - Lousiville
North Carolina
- Local Institution - Charlotte
Pennsylvania
- Local Institution - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00051038 record still lists
NCT00051038 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Entecavir is the first listed.
NCT00051038 lists 5 locations in 5 states (Connecticut, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00051038 about?
NCT00051038 is a clinical study titled "Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients". The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
What is the current status of trial NCT00051038?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2005-10.
What conditions does trial NCT00051038 study?
This clinical trial studies the following conditions: Hepatitis B.
What interventions are being tested in trial NCT00051038?
The interventions under investigation include: Entecavir (DRUG).
Who is sponsoring clinical trial NCT00051038?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051038 being conducted?
This trial has 5 study locations across Connecticut, Florida, Kentucky, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
RECRUITING · Phase 2
-
Liver Cancer Disparities in American Indian and Alaska Native Persons
RECRUITING · Phase 2
-
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
ACTIVE NOT RECRUITING · Phase 2
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia